Urologic Imaging

What Is the Next Step for a Large (≥4 cm) Indeterminate Adrenal Mass?

·
What Is the Next Step for a Large (≥4 cm) Indeterminate Adrenal Mass?

An asymptomatic 62-year-old patient undergoes an abdominal CT for unrelated, vague abdominal pain. The scan is unremarkable except for an incidental finding: a 5 cm left adrenal mass. The mass is solid, measures 45 Hounsfield units on the non-contrast phase, and does not have the characteristic low density of a benign adenoma or the macroscopic fat of a myelolipoma. The patient has no known history of malignancy. As the ordering clinician, you are now faced with a critical decision: what is the next step to characterize this large, indeterminate adrenal mass? This article details the specific clinical workflow for this scenario, explaining why, according to the American College of Radiology (ACR) Appropriateness Criteria, further adrenal-specific imaging and even biopsy are considered Usually Not Appropriate.

Who Fits This Clinical Scenario for a Large Indeterminate Adrenal Mass?

This guidance applies to a very specific patient presentation. It is crucial to ensure your patient matches these criteria before applying this workflow, as small variations can lead to a different diagnostic pathway.

Inclusion Criteria for This Workflow:

  • Adrenal Mass Size: The mass is greater than or equal to 4 cm in its largest dimension. This size threshold is a key factor that increases the suspicion for malignancy.
  • Indeterminate Features: On initial imaging (typically a non-contrast or single-phase contrast-enhanced CT), the mass lacks features that would definitively classify it as benign. This means it is not a simple cyst and does not have a density of ≤10 Hounsfield Units (HU) on non-contrast CT or contain macroscopic fat, which would suggest a myelolipoma.
  • No History of Malignancy: The patient has no known current or prior cancer. The presence of a known primary malignancy would significantly alter the differential diagnosis, making an adrenal metastasis a primary concern.

Exclusion Criteria (These Patients Require a Different Approach):

  • Smaller Masses: Patients with indeterminate adrenal masses less than 4 cm follow a different algorithm, often involving dedicated adrenal-protocol CT or MRI for further characterization.
  • Known Primary Cancer: If the patient has a history of a primary malignancy known to metastasize to the adrenal glands (e.g., lung, renal, melanoma), the workup shifts to evaluating for metastatic disease. This is a separate ACR variant.
  • Diagnostically Benign Features: If the mass has clear benign features on the initial scan (e.g., <10 HU on non-contrast CT), the appropriate next step is typically no further workup.

What Diagnoses Are You Working Up in This Scenario?

For an adrenal mass measuring 4 cm or larger, the clinical concern shifts significantly toward ruling out malignancy. While many adrenal masses are benign, size is one of the most important predictors of cancer. The differential diagnosis in this scenario is prioritized by clinical risk.

Adrenocortical Carcinoma (ACC): This is the primary concern and the main reason for the aggressive workup of large adrenal masses. ACC is a rare but highly aggressive malignancy. Approximately 50% of ACCs are larger than 6 cm at diagnosis, and the 4 cm threshold is used to capture these cancers at a potentially curable stage. The imaging features are often nonspecific, including heterogeneous enhancement, central necrosis, calcification, and local invasion.

Pheochromocytoma: This neuroendocrine tumor arises from the adrenal medulla and can secrete catecholamines, leading to potentially life-threatening hypertensive crises. While often benign, they can be malignant. Large pheochromocytomas can appear complex and heterogeneous on imaging, mimicking ACC. It is critically important to biochemically exclude a pheochromocytoma before any invasive procedure, including biopsy.

Benign Adrenal Adenoma: While most adenomas are small (<4 cm), they can occasionally grow to be large. A large, lipid-poor adenoma can be radiologically indeterminate and indistinguishable from ACC on initial imaging alone. However, the probability of malignancy increases with size, making a presumptive diagnosis of a benign adenoma less safe for larger lesions. Other Rare Possibilities: Less common considerations include adrenal metastasis from an unknown primary tumor, lymphoma, ganglioneuroma, or hemorrhagic cysts. However, the immediate clinical priority is to address the risk of ACC and pheochromocytoma.

Why Are Further Imaging and Biopsy ‘Usually Not Appropriate’ for This Mass?

For a large (≥4 cm), indeterminate adrenal mass in a patient without a known cancer history, the ACR panel rates nearly all subsequent adrenal-specific imaging studies, including biopsy, as Usually Not Appropriate. This counterintuitive recommendation stems from a shift in clinical priority from characterization to management, driven by the significant risk of malignancy.

The core rationale is that the size of the mass alone is often an indication for surgical consultation and potential resection. Further imaging is unlikely to definitively rule out Adrenocortical Carcinoma (ACC) and may delay definitive management.

Image-guided biopsy of the adrenal gland is rated Usually Not Appropriate. There are two major risks:
1. Tumor Seeding: If the mass is an ACC, percutaneous biopsy carries a significant risk of needle-tract seeding, which can turn a potentially curable localized cancer into an incurable one.
2. Pheochromocytoma Crisis: Biopsying an unsuspected pheochromocytoma can provoke a massive release of catecholamines, leading to a severe, potentially fatal hypertensive crisis. Biochemical screening must always precede any consideration of biopsy.

Similarly, other advanced imaging modalities are also rated Usually Not Appropriate at this stage:

  • CT abdomen without and with IV contrast (Radiation: ☢☢☢☢ 10-30 mSv) and MRI abdomen without and with IV contrast (Radiation: 0 mSv) are both rated Usually Not Appropriate. While these adrenal-protocol studies are excellent for characterizing smaller adenomas (by calculating contrast washout for CT or detecting signal loss on out-of-phase sequences for MRI), their ability to reliably distinguish a large benign adenoma from an early ACC is limited. Given that surgical resection is already strongly considered based on size, the information gained from these studies may not change the management plan and would only delay referral.

The clinical pathway pivots away from imaging characterization and toward biochemical evaluation and surgical planning.

What’s Next After Finding a Large Indeterminate Adrenal Mass? Downstream Workflow

Once a ≥4 cm indeterminate adrenal mass is identified, the workflow should proceed methodically to ensure patient safety and timely diagnosis. The focus is on biochemical testing and specialist consultation, not more imaging.

Step 1: Mandatory Biochemical Evaluation
Before any other step, assess the mass for hormonal activity. This is essential for surgical planning and to prevent peri-procedural complications.

  • Rule out Pheochromocytoma: Order plasma free metanephrines or 24-hour urinary fractionated metanephrines and catecholamines. This is the most critical initial test. A positive result requires an endocrinology consult and appropriate alpha- and beta-blockade before any surgical intervention.
  • Rule out Cushing’s Syndrome (Cortisol Excess): Perform a 1-mg overnight dexamethasone suppression test. A failure to suppress serum cortisol suggests autonomous cortisol secretion.
  • Assess for Hyperaldosteronism: If the patient has hypertension or hypokalemia, check a plasma aldosterone concentration and plasma renin activity to calculate the aldosterone-to-renin ratio.

Step 2: Surgical Consultation
Simultaneously with the biochemical workup, the patient should be referred to a surgeon with expertise in adrenal surgery (typically a urologist or endocrine surgeon). For most healthy patients with a non-functional, indeterminate adrenal mass ≥4 cm, surgical excision (adrenalectomy) is recommended for a definitive histopathologic diagnosis and to treat a potential ACC.

Step 3: Synthesize and Act

  • If biochemical tests are negative and the patient is a good surgical candidate: Proceed with planned adrenalectomy.
  • If biochemical tests are positive (e.g., for pheochromocytoma or Cushing’s): The patient requires medical management and optimization by an endocrinologist prior to surgery.
  • If the patient is a poor surgical candidate: The decision becomes more complex. A multidisciplinary discussion involving endocrinology, surgery, oncology, and radiology is warranted. In this specific context, after a negative biochemical workup, a biopsy might be reconsidered to guide non-surgical therapy, but this is an exception to the general rule.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup of a large adrenal mass requires avoiding several critical errors that can compromise patient safety and outcomes.

  • Pitfall 1: Ordering a Biopsy Prematurely. The single most dangerous pitfall is proceeding with a percutaneous biopsy before biochemically ruling out pheochromocytoma. This can be a fatal error.
  • Pitfall 2: “Watchful Waiting” Based on Lack of Symptoms. Do not be falsely reassured by the incidental nature of the finding or the absence of symptoms. For masses ≥4 cm, the risk of malignancy is substantial, and size alone is an indication for action.
  • Pitfall 3: Incomplete Hormonal Workup. Failing to perform a complete biochemical evaluation can lead to unexpected and dangerous intraoperative complications.
  • Pitfall 4: Relying on Advanced Imaging to Avoid Surgery. While adrenal-protocol CT or MRI are valuable for smaller masses, they cannot reliably exclude malignancy in a large, indeterminate mass. Delaying surgical referral for more imaging is generally not advised.

If the biochemical workup is positive, or if the initial imaging shows signs of local invasion or distant metastases, escalate immediately to a multidisciplinary tumor board or consult with endocrinology, endocrine/urologic surgery, and medical oncology.

Related ACR Topics and Tools

For a comprehensive overview of all clinical scenarios related to adrenal masses, further reading on imaging protocols, or to explore adjacent clinical questions, the following resources are available.

Frequently Asked Questions

Why isn’t an adrenal-protocol CT or MRI recommended for a 5 cm indeterminate adrenal mass?

For a mass ≥4 cm, the risk of adrenocortical carcinoma (ACC) is high enough that surgical resection is often the recommended next step for diagnosis and treatment, regardless of what a dedicated CT or MRI shows. These studies are less reliable at distinguishing a large benign mass from a malignant one, and performing them would likely delay the necessary surgical consultation without changing the ultimate management plan.

Is there any situation where a biopsy of a >4 cm adrenal mass is appropriate?

Yes, but it is rare. The primary indication is when a patient has a high suspicion of malignancy but is not a candidate for surgery. In this case, a tissue diagnosis might be needed to guide systemic therapy (like chemotherapy). However, a biochemical workup to rule out pheochromocytoma is absolutely mandatory before any biopsy is considered, and the decision should be made by a multidisciplinary team.

What is the most important first step after finding a large indeterminate adrenal mass?

The most critical first step is a biochemical workup to assess for hormonal function, especially to rule out a pheochromocytoma by checking plasma or urine metanephrines. This must be done before any invasive procedure or even finalizing a surgical plan, as a hormonally active tumor requires specific pre-operative medical management.

If the mass is 3.5 cm instead of 4.5 cm, does the recommendation change?

Yes, significantly. For an indeterminate adrenal mass between 2 and 4 cm, the ACR guidelines are different. In that scenario, further imaging with a dedicated, non-invasive study like an adrenal-protocol CT (with washout analysis) or a chemical-shift MRI is often ‘Usually Appropriate’ to better characterize the lesion and potentially avoid surgery if it proves to be a benign adenoma.

Does the patient’s age affect the management of a large adrenal mass?

While the core principles remain the same, age and comorbidities heavily influence the risk-benefit analysis for surgery. In an older patient with significant medical issues, the risks of adrenalectomy may outweigh the benefits. In such cases, and after a negative biochemical workup, a multidisciplinary team might consider surveillance or even a biopsy if a diagnosis would alter non-surgical management.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026